ADMA (asymmetric dimethylarginine) is a cardiovascular risk factor and an endogenous inhibitor of NOS (nitric oxide synthase). ADMA is metabolized by DDAHs (dimethylarginine dimethylaminohydrolases). ADMA levels are increased in cardiovascular disorders associated with abnormal angiogenesis but the mechanisms are poorly understood. Recent studies show that altering ADMA metabolism in vivo and in vitro modulates the activity of Rho GTPases, key regulators of actin dynamics, endothelial cell motility and angiogenesis. In the present review, we consider this and other NO-dependent and -independent molecular mechanisms by which the DDAH/ADMA pathway regulates angiogenesis.
The DDAH/ADMA pathway in angiogenesis
The significance of the DDAH/ADMA pathway in angiogenesis has been demonstrated in a number of systems. Homozygous deletion of DDAH I in mice is lethal, whereas HT (heterozygous) deletion of the gene results in endothelial dysfunction, increased systemic vascular resistance and elevated systemic and pulmonary blood pressure [8] . Aortic ring explants from the DDAH I HT mice exhibit reduced sprouting in Matrigel, which is mimicked by the addition of exogenous ADMA in the wild-type background [9] . Further, reduction of DDAH I activity and ADMA accumulation in a mouse model of hypercholesterolaemia inhibits basal and FGF (fibroblast growth factor)-induced angiogenesis in the fibrovascular disc system [10] . This effect can be mimicked in normocholesterolaemic animals by administration of ADMA and reversed by oral administration of L-arginine [10] . By contrast, overexpression of DDAH in vitro or in vivo increases NO production and enhances angiogenic responses. DDAH I transgenic mice show increased blood vessel formation in a mouse model of hindlimb ischaemia and in the fibrovascular disc system [11, 12] and show improved endothelial regeneration after femoral artery injury [13] . DDAH I overexpression in glioma cells enhances tumour growth and increases blood content in tumours [14] , while DDAH II overexpression in mouse and human endothelial cell lines promotes spontaneous tubulogenesis in vitro [15] . ADMA also prevents proper alignment of endothelial cells and induces neointima formation after balloon injury of rabbit carotid artery [16] . These studies demonstrate that DDAH/ADMA plays a key role in the control of angiogenesis in vitro and in vivo.
Mechanisms by which DDAH/ADMA regulates angiogenesis
Angiogenesis depends on the activation, migration and proliferation of endothelial cells under the regulatory control of growth factors such as VEGF (vascular endothelial growth HUVECs were seeded on to collagen I gels and cultured in the presence of VEGF (25 ng/ml) or VEGF+ADMA (100 μM) in media containing 0.5% FCS (foetal calf serum). Cells were fixed and phase-contrast images were obtained after a 24 h incubation.
factor) and FGF. The ADMA/DDAH pathway is believed to regulate angiogenesis by influencing NO bioavailability [11, 12] . NO is generated from L-arginine by NOS, which has three isoforms: endothelial [eNOS (endothelial NOS)], inducible [iNOS (inducible NOS)] and neuronal [nNOS (neuronal NOS)]. Endothelium-derived NO is required for the pro-angiogenic activity of growth factors such as VEGF, transforming growth factor-β and FGF [1, [17] [18] [19] . Consistent with the role of NO in the ADMA/DDAH pathway, DDAH I gene deletion in mice leads to inhibition of angiogenic responses, similar to that seen in eNOS-knockout mice [9, 12, 17, 20] . NO stimulates endothelial cell proliferation, survival and motility, and enhances matrix invasion and tubulogenesis [1, [17] [18] [19] . Downstream mediators of NO, including cAMP-and cGMP-dependent protein kinases [PKA (protein kinase A) and PKG (protein kinase G)], Rho GTPases and ROS (reactive oxygen species), are likely to play a part. NO also modulates gene expression of factors that promote angiogenesis, such as αvβ3 integrin, and suppresses the production of antiangiogenic factors such as angiostatin, the degradation product of plasminogen [1] .
Rho GTPases as mediators of the effects of ADMA
The ADMA/DDAH pathway modulates the activity of Rho GTPases, key regulators of actin dynamics [9, 21] . Spatial and temporal changes in the activation of Rho GTPases Rac1, RhoA and Cdc42 (cell division cycle 42) are required in the control of spontaneous and directional endothelial cell motility. Rac1 and Cdc42 promote extension of the cell front and formation of new attachments, whereas RhoA controls the stability of focal adhesions and is required for the retraction of the trailing edge [22] .
Recent results show that ADMA activates RhoA and inhibits Rac1 and Cdc42 in cultured human endothelial cells and cells from DDAH I HT knockout mice and that this effect is prevented by overexpression of DDAH [9] . The effects of ADMA on Rho GTPase activity are mediated by NO and its downstream effector, PKG [9, 21] . PKG-mediated phosphorylation of RhoA at Ser 188 prevents RhoA activation at the cell membrane [23] . Consistent with this model, ADMA decreased the levels of pSer 188 -RhoA in cultured human pulmonary endothelial cells and cells from DDAH I HT knockout mice, resulting in activation of RhoA, increase in cell-substratum adhesion and inhibition of spontaneous endothelial cell motility in vitro [9] .
ADMA inhibits VEGF-induced tube formation in vitro ( Figure 1 ). This effect is associated with decreased phosphorylation of VASP (vasodilator-stimulated phosphoprotein) and a subsequent inhibition of Rac1 activity. VASP is a scaffolding protein that links adherens junction proteins and integrins to the actin cytoskeleton and regulates polymerization of cortical actin cytoskeleton [24, 25] . While it is not fully understood how NO/PKG-induced phosphorylation of VASP activates Rac1, interactions of VASP with Rac1 regulatory proteins such as p120Ras GAP (GTPase-activating protein), GTP exchange factors for Rac1, or the tight junction component ZO-1 (zonula occludens 1 protein), are likely to play a role [26, 27] . Rac1 is activated by overexpression of both wild-type VASP and its phosphomimetic mutant, S239D-VASP, in endothelial cells [21] , and increased NO/PKG-mediated phosphorylation of VASP enhances angiogenesis [28] . Consistent with these results, overexpression of wild-type VASP in the presence of ADMA restores VEGF-induced angiogenesis in vitro (Figure 2) . Interestingly, Rac1 inhibition in human pulmonary endothelial cells decreases the levels of pSer 239 -VASP [9] , indicating the presence of a feedback regulatory mechanism. ADMA inhibits VEGF-induced lamellipodia formation and reduces turnover of focal adhesions in endothelial cells, consistent with a decrease in Rac1 activity [28a] . These effects are likely to account for the antiangiogenic effects of ADMA. Lamellipodia are crucial for establishing directional Figure 2 Overexpression of VASP prevents the antiangiogenic effects of ADMA GFP (green fluorescent protein) or GFP-wild-type VASP were overexpressed in HUVECs by Amaxa nucleofection as described in [21] , seeded on to collagen I gels and cultured in the presence or absence of VEGF (25 ng/ml) or ADMA (100 μM) in media containing 0.5% FCS. After a 24 h incubation, images of the cells were taken under the phase-contrast microscope and mean tube length was calculated using ImageJ (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001. endothelial cell motility, matrix invasion and alignment into capillary networks [29] . In support of our observations, Rac1-deficient endothelial cells are unable to form lamellipodia or respond to VEGF, and endothelial-specific deletion of Rac1 is lethal due to aberrant developmental angiogenesis [30] . Interestingly, both DDAH I and eNOS can be found in lamellipodia of polarized cells [9, 31] , indicating the potential importance of localized NO production in cell responses to directional cues. Further, endothelial-specific Rac1 haploinsufficient mice (EC-Rac1 +/− ) show mild hypertension, impaired angiogenesis and decreased NO signalling [32] , reminiscent of the phenotype of the DDAH I HT [8, 9] and eNOS [17, 20] knockout mice, and highlighting the importance of a reciprocal relationship between NO and Rac1 activities. ADMA-induced activation of RhoA and inhibition of Rac1 may further reduce NO production by endothelial cells, enhancing endothelial dysfunction. RhoA and Rho kinase reduce eNOS activity and expression [33] , whereas Rac1 promotes eNOS gene transcription and increases eNOS mRNA stability and eNOS activity [32] .
Dysregulation of Rho GTPase activity by ADMA may also affect other processes important in angiogenesis.
ADMA de-stabilizes endothelial junctions as a result of Rac1 inhibition and RhoA activation in vitro and in vivo [21] . Destabilization of endothelial adherens and tight junctions precedes endothelial cell migration from pre-existing blood vessels, whereas rebuilding intercellular junctions is required for the assembly of new lumen-bearing cords.
Endothelial cell proliferation and apoptosis
Angiogenic morphogenesis requires tightly controlled regulation of apoptotic and proliferative pathways. ADMA was postulated to have pro-apoptotic and antiproliferative effects in some endothelial cell types [34, 35] , whereas others reported no effect [15, 9, 21] . ADMA induced HUVEC (human umbilical vein endothelial cell) apoptosis via p38 MAPK [p38 MAPK (mitogen-activated protein kinase)] activation and increased ROS, dependent on decreased NOS activity [34] . In our system, we did not observe any changes either in apoptosis or in ROS production [9,21,28a] . These discrepancies are likely to arise from differences in cell type, culture conditions or passage number.
Regulation of gene expression
Pro-angiogenic effects of DDAH are linked to up-regulation of VEGF expression and secretion [14, 15, 36, 37] , which can also occur in response to increased NO signalling [17, 18] . However, this mechanism may be DDAH II specific [15, 36, 37] , as only one report showed increased VEGF secretion in glioma cells overexpressing DDAH I [14] , and we did not observe changes in either VEGF expression and secretion or VEGFR-2 (VEGF receptor-2) activation in ADMAtreated HUVECs or HUVECs overexpressing DDAH I [28a] . Interestingly, up-regulation of VEGF expression in HUVECs by DDAH II did not depend on NOS activity but resulted from PKA-dependent activation of the transcription factor Sp1 (specificity protein 1) [36] . Pathophysiologically relevant doses of ADMA (2 μM) also affect the expression of several genes involved in the regulation of endothelial cell metabolism, growth, transcription and organization of the cell cytoskeleton [38] but the relevance of these changes in the antiangiogenic effects of ADMA remains to be established.
Oxidative stress and inflammation
Increased oxidative stress and chronic inflammation are associated with abnormal vascular morphogenesis [39] . ADMA can increase superoxide production in some cell types as a result of eNOS uncoupling [40] [41] [42] . Although ADMA did not stimulate ROS formation in pulmonary artery endothelial cells in vitro [9, 21] , a role of ROS in angiogenesis in vivo cannot be excluded. DDAH enzymes are redox-sensitive and increased ADMA levels in animals and patients with Type 2 diabetes are linked to increased ROS generation [43] .
Regulation of NO production by ADMA might also modulate inflammatory responses, important in endothelial repair and angiogenesis. In support of this, in the DDAH I transgenic mice, vascular repair was enhanced, while inflammatory infiltrate was suppressed after femoral artery injury, as a result of increased NOS activity [13] . In addition, cardiac transplantation into DDAH I transgenic mice was associated with reduced myocardial oxidative stress, inflammation and tissue damage compared with wild-type mice [44] .
ADMA/DDAH and endothelial progenitor cells
Endothelial progenitor cells play an important role in angiogenesis and vasculogenesis [45] . ADMA was shown to inhibit mobilization, differentiation and function of endothelial progenitor cells [35] . In humans, plasma ADMA levels were correlated to the severity of coronary artery disease and inversely correlated with the number of circulating CD34+/CD133+ progenitor cells and colonyforming units [35] . Accordingly, a reduction in ADMA levels might accelerate endothelial regeneration by promoting mobilization of bone-marrow-derived endothelial cells [13] .
Summary
ADMA metabolism by DDAH regulates angiogenesis in vitro and in vivo. Reduction of endothelial NO production accounts for many of the effects of ADMA on endothelial cell migration, barrier function and angiogenesis, although changes in ROS production, inflammatory responses and altered gene expression are also likely to play a role. NO-dependent modulation of Rho GTPase activity is an important pathway by which ADMA mediates endothelial motility, cell-cell and cell-matrix interactions, essential for endothelial homoeostasis and for proper responses to pro-angiogenic growth factors such as VEGF (Figure 3 ).
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